GlassScriptPhysician profile
Rita M Owen
NPI 1528623618
$1,699.92
in general payments reported to CMS, 2019-2025
25 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $376 · 2023: $285 · 2024: $463 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.26 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.43 | 2021-2024 | |
| Organon LLC | $209.23 | 2022-2025 | Nexplanon |
| Astellas Pharma US INC | $157.50 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $154.82 | 2023-2025 | Gemtesa, Myfembree |
| Exeltis, USA INC. | $137.14 | 2021-2023 | Slynd |
| Csl Behring | $120.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $68.87 | 2021 | |
| Biogen, INC. | $58.86 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $52.37 | 2022 | |
| Kaleo, INC. | $39.62 | 2021 | |
| Biocryst US Sales Co., LLC | $36.48 | 2021 | |
| Daiichi Sankyo INC. | $27.38 | 2023 | Injectafer |
| Hologic Sales and Service, LLC | $23.57 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.21 | 2021 | |
| Urovant Sciences INC | $23.10 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $19.01 | 2022 | |
| Amgen INC. | $16.95 | 2022 | |
| Millicent US INC | $16.74 | 2025 | Intrarosa, Femlyv |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2021 | |
| Pfizer INC. | $15.82 | 2025 | |
| Glaxosmithkline, LLC. | $15.71 | 2021 | |
| Mayne Pharma Commercial LLC | $15.69 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $11.65 | 2022 | |
| Genzyme Corporation | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.